Perrigo Company PLC (PRGO)

NYSE
Currency in USD
26.22
-0.77(-2.85%)
Closed·
After Hours
26.60+0.38(+1.45%)
·
PRGO Scorecard
Full Analysis
High shareholder yield
High dividend Yield
Fair Value
Day's Range
26.2126.94
52 wk Range
23.1430.93
Key Statistics
Edit
Prev. Close
26.99
Open
26.78
Day's Range
26.21-26.94
52 wk Range
23.14-30.93
Volume
1.58M
Average Volume (3m)
1.8M
1-Year Change
-14.87%
Book Value / Share
31.98
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PRGO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
34.60
Upside
+31.96%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 22 consecutive years
Show more

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Employees
8379

Perrigo Company PLC SWOT Analysis


Opill's Impact
Explore how Perrigo's OTC oral contraceptive launch could boost EPS by 10-11%, potentially transforming the company's financial landscape
Financial Outlook
Delve into Perrigo's projected sales of $4,594M for FY2024 and $4,855M for FY2025, with adjusted EPS estimates of $2.57 and $3.37 respectively
Market Positioning
Learn about Perrigo's strong foothold in the OTC private label market, benefiting from consumer trends favoring affordable self-care products
Analyst Perspectives
Discover why analysts maintain a positive outlook, with price targets ranging from $35 to $42, highlighting Perrigo's potential as a free cash flow generato
Read full SWOT analysis

Perrigo Company PLC Earnings Call Summary for Q3/2024

  • Net sales down 3.2% YoY, but operating income up 21.3% and EPS up 27% to $0.81; 2024 adjusted EPS guidance reaffirmed at $2.50-$2.65
  • Project Energize achieves $95M in gross savings YTD; Supply Chain Reinvention expected to save $100-120M annually by 2025
  • Infant formula segment shows recovery with 3% net sales increase YoY; focus on stabilizing this area and growing OTC medications
  • Company aims to enhance free cash flow, deleverage balance sheet, and invest in consumer packaged goods capabilities
  • Management plans to reduce total debt and interest expenses by 2025; increase R&D and advertising to boost competitiveness
Last Updated: 07-11-2024, 01:10 am
Read Full Transcript

Compare PRGO to Peers and Sector

Metrics to compare
PRGO
Peers
Sector
Relationship
P/E Ratio
−21.9x7.6x−0.5x
PEG Ratio
0.01−0.400.00
Price/Book
0.8x0.8x2.6x
Price / LTM Sales
0.8x1.0x2.9x
Upside (Analyst Target)
30.9%47.9%50.4%
Fair Value Upside
Unlock41.2%9.1%Unlock

Analyst Ratings

3 Buy
3 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 34.60
(+31.96% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -1.20%
Dividend Yield
4.30%
Industry Median 1.79%
Annualised payout
1.16
Paid quarterly
5-Years Growth
+5.50%
Growth Streak

Earnings

Latest Release
May 07, 2025
EPS / Forecast
0.60 / 0.55
Revenue / Forecast
1.04B / 1.09B
EPS Revisions
Last 90 days

FAQ

What Is the Perrigo (PRGO) Stock Price Today?

The Perrigo stock price today is 26.22.

What Stock Exchange Does Perrigo Trade On?

Perrigo is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Perrigo?

The stock symbol for Perrigo is "PRGO."

Does Perrigo Pay Dividends? What’s The Current Dividend Yield?

The Perrigo dividend yield is 4.42%.

What Is the Perrigo Market Cap?

As of today, Perrigo market cap is 3.62B.

What Is Perrigo's Earnings Per Share (TTM)?

The Perrigo EPS (TTM) is -1.20.

When Is the Next Perrigo Earnings Date?

Perrigo will release its next earnings report on 05 Aug 2025.

From a Technical Analysis Perspective, Is PRGO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.